Pozen took another step toward getting its anti-migraine drug MT 100 approved on Thursday, filing a new drug application with the US Food and Drug Administration.

The company said that the FDA had accepted the application and would review it early next year.

John Plachetka, president and chief executive officer of Pozen, reiterated the market for an alternative treatment of migraine headaches, is quite large.

“In a recently published study for the National headache Foundation, eight out of 10 migraine sufferers said they would consider taking a new therapy with similar efficacy but fewer side effects than current prescription medicines,” he said. “MT 100 is designed to fit this need, and if approved, may provide patients with an important new treatment option.”

Pozen (Nasdaq: POZN) already had moved MT 100 forward for approval in Europe. Last October, a market authorization application was filed in the United Kingdom as a first step toward getting approval in the European Union. Pozen also already has signed a distribution deal for the drug in four Scandinavian countries.

The NDA for MT 100 follows closely on other good news for the firm — its drug co-development deal with GlaxoSmithKline for MT 400. That deal already has generated a $25 million payment to Pozen.

Pozen: www.pozen.com